Return to the home page of the Diabetes Monitor
diabetes news for April 2009
Advertisement


 

go to home page read about us contact us read our disclaimer go to the index read our mission statement read our privacy policy search our website go to the site map find out what's new

    • April 27, 2009    The latest CDC information about the swine flu outbreak is posted at their website, at Human Swine Influenza Investigation.

    • April 20, 2009    Diabetics are increasingly risking life and limb by cutting back on - or even going without - doctor visits, insulin, medicines and blood-sugar testing as they lose income and health insurance in the recession, an Associated Press analysis has found. [Story at msnbc.com: Diabetics risking life and limb amid recession: Patients increasingly cutting back on insulin and medical care, report finds.]

    • April 13, 2009    Treatment with the glitazone class of diabetes drugs ( (Avandia and Actos) leads to a "modest" increase in the risk of diabetic macular edema-a common complication that can lead to vision loss. Glitazone Use Associated with Diabetic Macular Edema. American Journal of Ophthalmology Volume 147, Issue 4, Pages 583-586 (April 2009). [Story at ScienceDaily. Abstract at AJO; full text at AJO, requires subscription.]

    • April 6, 2009    Two new drugs for diabetes got their turn before a Food and Drug Administration advisory panel this week, although with different results. On April 1, 2009, the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 10 to 2 that the investigational diabetes drug saxagliptin (Onglyza, Bristol-Myers Squibb/AstraZeneca, a potential competitor for Januvia) does not put type 2 diabetes patients at an increased risk for cardiovascular events. The next day, liraglutide (Victoza, Novo Nordisk, a potential competitor for Byetta) didn't fare as well when the advisory panel declined to recommend approval It was a thyroid cancer signal that emerged in animal studies that worried the panel. [Story at theheart.org: Saxagliptin gets favorable FDA panel review, while liragutide not recommended for approval. Briefing documents are at the FDA website: Endocrinologic and Metabolic Drugs Advisory Committee.]

    • April 1, 2009    Smiths Medical announced its intent to stop manufacturing and selling the Deltec Cozmo® insulin pump. [Information at www.delteccozmoupdate.com.]
    
    
    Advertisement
    
    




Advertisements







  [Top]   Last month's diabetes news  
Advertisement
Read the Diabetes Monitor
 

Return to the home page of the Diabetes Monitor Go to the index Search this website Go to the site map Read our copyright noticeRead our copyright notice Send us an e-mail at info@diabetesmonitor.com